Related Experiment Video
Updated: Sep 3, 2025
11:13
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
1.7K
The Epigenetic Regulatory Protein CBX2 Promotes mTORC1 Signalling and Inhibits DREAM Complex Activity to Drive Breast
Lucie J Bilton1, Chloe Warren1, Rebecca M Humphries1
1Faculty of Health Sciences, University of Hull, Hull HU6 7RX, UK.
Cancers
|July 27, 2022
Summary
Chromobox 2 (CBX2) drives triple-negative breast cancer (TNBC) by silencing tumor suppressors. Inhibiting CBX2
Area of Science:
- Molecular Biology
- Oncology
- Epigenetics
Background:
- Chromobox 2 (CBX2) is a key component of polycomb repressive complex 1, involved in gene silencing.
- Elevated CBX2 expression is observed in triple-negative breast cancer (TNBC), a subtype with limited therapeutic strategies.
Purpose of the Study:
- To investigate the functional role of CBX2 in the progression of TNBC.
- To elucidate the molecular mechanisms by which CBX2 contributes to TNBC pathogenesis.
Main Methods:
- CBX2 knockdown and ectopic expression in TNBC cell models.
- Inhibition of CBX2 chromatin binding using a specific inhibitor (SW2_152F).
- RNA sequencing and gene set enrichment analysis to identify affected signaling pathways.
Main Results:
- CBX2 knockdown significantly reduced TNBC cell proliferation, dependent on its chromatin-binding ability.
- CBX2 inhibition downregulated oncogenic pathways, including mTORC1 and E2F signaling.
- CBX2 was found to repress mTORC1 inhibitors and the tumor suppressor RBL2, thereby inhibiting the DREAM complex and promoting cell proliferation.
Conclusions:
- CBX2 chromatin binding is essential for TNBC progression.
- Therapeutic targeting of CBX2 may offer a novel strategy for TNBC by repressing mTORC1 and promoting senescence via the DREAM complex.
- CBX2's role in repressing RBL2 and impacting senescence suggests potential therapeutic applications in other cancer types.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
01:22PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
02:23Master Transcription Regulators
7.0K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.0K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K